Nivolumab adjuvant for treating for stage IIB/IIC resected melanoma

Nivolumab is in clinical development as a therapy to be given to patients who have had stage IIB-IIC melanoma removed via surgery but who are at high risk of recurrence. Melanoma is a type of skin cancer that is commonly caused by sun exposure and is often first noticed as a new mole or a change in the colour, shape, or size of an existing mole. Stage IIB and IIC melanoma is where the cancer has developed through only the top 2-4mm of the skin and may also be ulcerated which means the top layer of skin covering the cancer has started to break down. Currently, there are no recommended treatments to help prevent melanoma from coming back after the cancer has been removed by surgery, in patients who are at high risk of recurrence.